Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC

PHASE2RecruitingINTERVENTIONAL

Enrollment

126

Participants

Timeline

Start Date

August 18, 2023

Primary Completion Date

August 1, 2025

Study Completion Date

August 1, 2030

Conditions

ALK Positive Non-small Cell Lung Cancer

Interventions

DRUG

Loratinib

Continuous daily PO dosing of lorlatinib 100mg QD.

Trial Locations (1)

RECRUITING

Guangdong Provincial Perople's Hospital, Guangzhou

All Listed Sponsors

lead

Guangdong Association of Clinical Trials

OTHER